title: Prevalence of hepatitis B markers in patients with hepatitis C infection in north-eastern Poland: risk factors and vaccine use.
abstract: We evaluated the prevalence of hepatitis B virus (HBV) markers and established HBV vaccination status among 111 patients with hepatitis C virus (HCV) infection. A history of HBV immunisation was recorded in 30 patients (27.0%) and only 17/30 (66.7%) had anti-HBs level > or =10 mIU/ml. All patients were HBsAg-negative and 22.2% of nonvaccinated subjects had evidence of HBV infection as determined by anti-HBc presence. Among patients with anti-HBc in 7/18 cases (38.9%) anti-HBc was the only marker of HBV infection (without anti-HBs). The prevalence of anti-HBc was significantly higher among patients who reported a history of acute hepatitis. In conclusion the prevalence of HBV markers in patients with HCV infection in north-eastern Poland is similar to the prevalence in general population, which suggests no increased risk for nosocomial HBV infection among those individuals. HCV infection seems to favour unusual serological pattern of HBV infection with anti-HBc as the only marker. HBV vaccine use is low among patients with HCV infection in north-eastern Poland.
authors.affiliation: Department of Infectious Diseases, University Medical School in Białystok, Poland. doctors@friko.onet.pl
authors.forename: S
authors.initials: S
authors.lastname: Chlabicz
authors.forename: A
authors.initials: A
authors.lastname: Grzeszczuk
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000175:diagnosis* / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000627:therapeutic use; D006526:Hepatitis C / Q000175:diagnosis* / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011044:Poland / Q000453:epidemiology; D015995:Prevalence; D012307:Risk Factors; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D018937:Hepatitis C Antibodies; D014761:Viral Hepatitis Vaccines